Companies › Theravance Biopharma
1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ampreloxetine Norepinephrine transporter inhibitor | SLC6A2 | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05696717 | Ampreloxetine | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension | Cardiovascular | Jan 2028 |
Cash and short-term investments of $388m on 2026-06-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Axsome Therapeutics Supernus Pharmaceuticals Currax Pharmaceuticals Otsuka Resilient Pharmaceuticals Remedy Definium Therapeutics US
Boston Scientific Inhibikase Therapeutics Kiniksa Pharmaceuticals International CeleCor Therapeutics MedTrace Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.